Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest breast cancers Stories

2013-10-15 08:33:34

Also Releases Results from National Harris Survey Revealing Widespread Confusion about BRCA Testing MADISON, N.J., Oct. 15, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of BRCAvantage(TM), a suite of four new lab-developed genetic tests (LDT) that identify mutations in BRCA1 and BRCA2 genes, which are associated with increased risk of inherited breast and ovarian cancers. Serving...

2013-08-20 17:10:19

Based on data from a multi-site imaging trial involving more than 2,600 women, researchers say breast lesions categorized as 'probably benign' on supplemental screening ultrasound could be re-evaluated with imaging in 12 months, reducing patient anxiety, follow-up exams and unnecessary biopsies. Results of the study are published online in the journal Radiology. In the study, a team of researchers analyzed data from the American College of Radiology Imaging Network (ACRIN) trial 6666, in...

2013-08-12 12:27:34

BOSTON, Aug. 12, 2013 /PRNewswire-USNewswire/ -- In a new paper in Cancer Cell, a team led by Judy Lieberman, PhD, of Boston Children's Hospital's Program in Cellular and Molecular Medicine reports "triple-negative" breast cancers may be vulnerable to drugs that attack the proteasome. This cellular structure acts as the cell's waste disposal, breaking down damaged or unneeded proteins. These cancers, which lack the three major therapeutic markers for breast cancer--the estrogen,...

2013-05-31 08:24:39

Prognostic Information from Oncotype DX in Metastatic Breast Cancer Indicates Importance of Biology Revealed by the Test Across Continuum of the Disease REDWOOD CITY, Calif., May 31, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of 10 studies being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, underscoring the company's commitment to optimizing cancer treatment. New data include studies of the Oncotype DX®...

2013-05-02 08:37:18

Accurate, Rapid, Cost-Effective Blood Test Aims to Confirm True Negative Findings While Halving the Rate of False Negative Mammography Results MIAMI, May 2, 2013 /PRNewswire/ -- Eventus Diagnostics, Inc. (EventusDx) today announced that it has received CE mark designation for its Octava Pink(TM) breast cancer test intended for confirmatory use in women who have received negative mammography results. The National Cancer Institute (NCI) estimates that screening mammograms miss about...

2012-12-03 20:57:17

Prostate cancer drug shows promise in triple-negative and estrogen-positive breast cancer Breast cancers are defined by their drivers — estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer treatment options — this aggressive form of breast cancer without ER, PR or HER2, which was thought not to be driven by hormones, is known as triple negative. A decade ago,...

2012-09-28 02:24:46

REDWOOD CITY, Calif., and VIENNA, Sept. 28, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of data that support expanded use of the Oncotype DX® tests in optimizing treatment decisions for breast and colon cancer patients at various stages of disease. The new data confirm the ability of the Oncotype DX colon cancer test to predict recurrence risk in stage II and stage III colon cancer patients, and exploratory analyses have identified 16 genes...

2012-06-01 10:22:20

REDWOOD CITY, Calif., June 1, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of 18 studies being presented at the American Society for Clinical Oncology(®) (ASCO(®)) Annual Meeting taking place June 1-5 in Chicago, Illinois. New data includes validation of the Oncotype DX® colon cancer test in both stage II and stage III disease, the company's first prostate needle biopsy development study, and further evidence of the clinical value of the...

2012-05-16 14:22:32

REDWOOD CITY, Calif., May 16, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from 18 separate studies covering breast, colon and prostate cancers will be presented at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting, reflecting the company's ongoing commitment to the research, development and delivery of innovative diagnostic tests to help individualize cancer treatment decisions. The annual meeting is taking place June 1-5, 2012 in...

2012-03-21 14:13:03

Results from one of the longest-running national breast cancer screening programs have shown that it has contributed to a drop in deaths from the disease, that any harm caused by the screening, such as false positives and over-diagnosis, has been limited, and that the costs have been reasonable. The Dutch population-based mammography breast cancer screening program began in 1989, and today (Wednesday) Mr Jacques Fracheboud, a senior researcher at the Erasmus University Medical Center...